Active Hexose Correlated Compound (AHCC) promotes an intestinal immune response in BALB/c mice and in primary intestinal epithelial cell culture involving toll-like receptors TLR-2 and TLR-4
- 685 Downloads
Active Hexose Correlated Compound (AHCC®) is a cultured mushroom extract that is commercially available and promoted for immune support. Available data suggest that AHCC supplementation affects immune cell populations and immune outcomes, including natural killer cell response to infection. The mechanism by which AHCC exerts its effects is not well understood. The present work aimed to characterize the immunomodulatory activity of AHCC in the gut and to study the effects of AHCC on toll-like receptor (TLR) signaling in intestinal epithelial cells (IECs).
BALB/c mice were fed AHCC by gavage. In vivo activities were assessed by immunohistochemistry and cytokine production. The effects of AHCC on ex vivo primary cell culture from IECs were examined after challenge with LPS or E. coli alone or in the presence of anti-TLR-2 and TLR-4 blocking antibodies.
Feeding AHCC resulted in increased IgA+ cells in the intestine and increased sIgA, IL-10, and IFN-γ in the intestinal fluid. In IECs, contact with AHCC increased IL-6 production but not to the pro-inflammatory level of positive controls, LPS and E. coli. Blocking TLR-2 and TLR-4 reduced the induction of IL-6 by AHCC, suggesting that these innate receptors are involved in generating the immune response of IECs to AHCC.
AHCC may play a role in the orchestration of immune response and the maintenance of immune homeostasis in part by priming the TLR-2 and TLR-4 gate at the intestinal epithelium. Such a response is likely due to the recognition of non-pathogenic food-associated molecular patterns (FAMPs) such as those found associated with other mushroom or yeast-derived compounds.
KeywordsAHCC Toll-like receptor E. coli Infection Mushroom Innate FAMP
We would like to thank Mr. Jairo Duarte for his help in the isolation of the intestinal epithelial cells. This work was made possible by a non-restrictive research grant from the manufacturer of AHCC, Amino Up Chemical Company, Sapporo, Japan.
Conflict of interest
Dr. Kohei Homma is employed at Amino Up Chemical Co., Ltd. as a research scientist. Amino Up Chemical is the developer and manufacturer of the AHCC product used in this study. The author has not received personal financial gain from sales of the AHCC product. All findings and views expressed in this paper are those of the authors and do not necessarily reflect the views of Amino Up Chemical. As the vice president of scientific and regulatory affairs for Atrium Innovations, Dr. Barry Ritz is involved in the commercialization of many natural products, including AHCC. Currently, two atrium companies, Douglas Laboratories and Pure Encapsulations, commercialize products that contain AHCC as an ingredient. The other authors have no conflict of interest to declare.
- 1.Ritz BW, Nogusa S, Ackerman EA, Gardner EM (2006) Supplementation with active hexose correlated compound increases the innate immune response of young mice to primary influenza infection. J Nutr 136(11):2868–2873Google Scholar
- 4.Daddaoua A, Martínez-Plata E, Ortega-González M, Ocón B, Aranda CJ, Zarzuelo A et al (2013) The nutritional supplement Active Hexose Correlated Compound (AHCC) has direct immunomodulatory actions on intestinal epithelial cells and macrophages involving TLR/MyD88 and NF-κB/MAPK activation. Food Chem 136(3–4):1288–1295CrossRefGoogle Scholar
- 6.Okuyama T, Yoshigai E, Ikeya Y, Nishizawa M (2013) Active Hexose Correlated Compound extends the lifespan and increases the thermotolerance of nematodes. Funct Foods Health Dis 3(6):166–182Google Scholar
- 15.Gould D. (2010) Causes, prevention and treatment of Escherichia coli infections. Nurs Stand 7;24(31):50–56; quiz 58Google Scholar
- 16.Dho-Moulin M, Fairbrother JM (1999) Avian pathogenic Escherichia coli (APEC). Vet Res 30(2–3):299–316Google Scholar
- 18.Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PSC, Goulet J, Tompkins TA (2005) Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-Induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun 73(8):5183–5188CrossRefGoogle Scholar
- 20.Vinderola G, Matar C, Perdigón G (2005) Role of intestinal epithelial cells in immune effects mediated by Gram-positive probiotic bacteria: involvement of Toll-like receptors. Clin Diagn Lab Immunol 12(9):1075–1084Google Scholar
- 23.Slorach EM, Campbell FC, Dorin JR (1999) A mouse model of intestinal stem cell function and regeneration. J Cell Sci 112(18):3029–3038Google Scholar
- 29.Wang Y, Ames N, Li S, Jones P, Khafipour E (2014) High molecular weight barley β-glucan supports bacterial populations beneficial for gut health. FASEB J 28(1 Supplement):647.45Google Scholar